Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) from a hold rating to a sell rating in a research note released on Tuesday, January 9th.

According to Zacks, “Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France. “

Other research analysts have also recently issued reports about the stock. Roth Capital set a $14.00 price objective on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share and gave the company a buy rating in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a strong sell rating to a sell rating in a report on Thursday, January 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $21.50.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) traded up $0.10 during midday trading on Tuesday, reaching $10.61. 551,619 shares of the company were exchanged, compared to its average volume of 277,572. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a fifty-two week low of $7.52 and a fifty-two week high of $12.30. The company has a market capitalization of $421.28, a P/E ratio of 5.58 and a beta of 1.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.53 and a quick ratio of 1.47.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.13. The business had revenue of $39.68 million during the quarter, compared to analysts’ expectations of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the company posted ($0.08) earnings per share. analysts anticipate that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.32 earnings per share for the current year.

In other Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share news, Director Craig R. Stapleton sold 254,265 shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.35, for a total value of $2,377,377.75. Following the sale, the director now owns 253,413 shares of the company’s stock, valued at $2,369,411.55. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Craig R. Stapleton purchased 140,000 shares of the stock in a transaction dated Friday, December 15th. The stock was acquired at an average cost of $8.67 per share, for a total transaction of $1,213,800.00. The disclosure for this purchase can be found here. 5.07% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of AVDL. PNC Financial Services Group Inc. raised its position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% in the second quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after purchasing an additional 10,532 shares during the period. Nine Chapters Capital Management LLC bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter valued at approximately $132,000. Sei Investments Co. raised its position in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after purchasing an additional 2,900 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the second quarter valued at approximately $181,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter valued at approximately $184,000. 67.75% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally reported by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-lowered-to-sell-at-zacks-investment-research/1821283.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.